Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358107 · ClinicalTrials.gov registry record
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
A clinical trial of Adrenocortical Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT04358107: Active study of Adrenocortical Carcinoma, sponsored by National Cancer Institute (NCI).
NCT04358107 is a study of Adrenocortical Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,000 participants, above the 239-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (318% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04358107, a study of Adrenocortical Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ones. They want to learn more about ACC by looking at data from previous studies. Objective: To characterize the overall prognosis and treatment responses in people with ACC with various systemic therapies and correlate them with age, sex, race, and disease burden. Eligibility: People with ACC enrolled on any of the following studies: 92-C-0268, 93-C-0200, 00-C-0044, 01-C-0129, 04-C-0011, 09-C-0242, 08-C-0176, 10-C-0203, 13-C-0114, and 14-C-0029 Design: Study researchers will review participants medical records. They will collect the following data: Medical record numbers Demographics (such as age, sex, and race) Treatments (such as surgeries, radiology procedures, and systemic treatments) Time of disease progression between treatments and genetic/molecular data (if available) Time of diagnosis/time of death. All data will be kept in secure network drives or sites. Participants who opted out of future use of data on their prior studies will be not be included in this study.
Primary Outcome
prognosis and treatment responses among patients with ACC correlated with age, sex, race and disease burden
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT04358107 still lists
NCT04358107 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 239-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (318% higher).
The record links to 1 condition, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04358107 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04358107 about?
NCT04358107 is a clinical study titled "Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)". Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ...
What is the current status of trial NCT04358107?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2020-04-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04358107 study?
This clinical trial studies the following conditions: Adrenocortical Carcinoma.
Who is sponsoring clinical trial NCT04358107?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04358107 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenocortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04358107's enrollment target sits among peer trials
1,000 2nd of 8 the highest of 8 other Adrenocortical Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adrenocortical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI